Ongoing important trials
BESPOKE CRC — ctDNA-guided therapy (observational)
BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer
- Phase
- N/A
- Recruitment
- Completed
- Results maturity
- Primary analysis
- Publication
- Congress + peer-reviewed
- Regulatory approval
- No regulatory approval
- NCT
- NCT04264702
- Registry checked
- 2026-10-29
- Editorial update
- 2026-10-29
Not a treatment recommendation. Experimental or ongoing research does not by itself replace standard care.
For patients
What is being studied? Researchers studied whether a post-surgery blood test can detect recurrence risk earlier.
Why promising? Large observational cohort links ctDNA+ to worse DFS; strengthens MRD clinical-utility hypotheses.
What is not proven? Randomized intervention superiority (left to CIRCULATE-US); assays are not interchangeable.
Is this standard care today? This listing alone does not replace standard care; approval and guideline context require clinician judgment.
For clinicians
NCT04264702; JCO 2025 abstract final sub-cohort. ClinicalTrials.gov status unclear — note in record; clinician review.
Cancer / population: Colon, Rectum — Rezeke evre I–IV CRC (analiz alt kohortları evre II–III)
Intervention: Gözlemsel ctDNA izlemi ± klinisyen kararları
Primary endpoint: Adjuvan karar etkisi / asemptomatik nüks tespiti (protokol)
Limitations: Gözlemsel; CT.gov UNKNOWN; randomize karar kanıtı değil.